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Abstract
Tightly associated with blood vessels in their perivascular niche, human mesenchymal stem cells (MSCs) closely interact with endothelial cells
(ECs). MSCs also home to tumours and interact with cancer cells (CCs). Microparticles (MPs) are cell-derived vesicles released into the extra-
cellular environment along with secreted factors. MPs are capable of intercellular signalling and, as biomolecular shuttles, transfer proteins and
RNA from one cell to another. Here, we characterize interactions among ECs, CCs and MSCs via MPs and secreted factors in vitro. MPs and
non-MP secreted factors (Sup) were isolated from serum-free medium conditioned by human microvascular ECs (HMEC-1) or by the CC line
HT1080. Fluorescently labelled MPs were prepared from cells treated with membrane dyes, and cytosolic GFP-containing MPs were isolated
from cells transduced with CMV-GFP lentivirus. MSCs were treated with MPs, Sup, or vehicle controls, and analysed for MP uptake, prolifera-
tion, migration, activation of intracellular signalling pathways and cytokine release. Fluorescently labelled MPs fused with MSCs, transferring
the fluorescent dyes to the MSC surface. GFP was transferred to and retained in MSCs incubated with GFP-MPs, but not free GFP. Thus, only
MP-associated cellular proteins were taken up and retained by MSCs, suggesting that MP biomolecules, but not secreted factors, are shuttled
to MSCs. MP and Sup treatment significantly increased MSC proliferation, migration, and MMP-1, MMP-3, CCL-2/MCP-1 and IL-6 secretion
compared with vehicle controls. MSCs treated with Sup and MPs also exhibited activated NF-jB signalling. Taken together, these results sug-
gest that MPs act to regulate MSC functions through several mechanisms.
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Introduction
Mesenchymal stem cells (MSCs) have long attracted attention
because of their differentiation capabilities, yet their most interesting
behaviours may involve their interactions with other cells. For exam-
ple, there is strong evidence to suggest that MSCs occupy a perivas-
cular niche in a variety of vascularized tissues [1–5]. In fact, MSCs
have been described as a type of pericyte, a microvascular cell type
analogous to the smooth muscle cells of macrovessels [5, 6]. MSCs
express pericyte markers [1, 2], and exhibit pericyte activities, such
as enhancing vessel formation and stabilization through paracrine
interactions [3, 4]. Furthermore, both MSCs and pericytes display
similar differentiation capabilities [5–8]. As pericytes, wrapped
around blood vessels in their perivascular niches, MSCs closely inter-
act with endothelial cells (ECs), the primary vascular cell type that
makes up the walls of blood vessels. MSCs are also able to leave their
perivascular niche during wound healing and disease conditions. For
example, MSCs home to tumours, where they interact with both can-
cer cells (CCs) and ECs [9, 10].
Mesenchymal stem cells naturally interact with ECs and CCs, and
vice versa, and studies involving crosstalk between MSCs and these
cell types have traditionally been broken down into 3 main compo-
nents: (i) cell–cell [11], (ii) cell–matrix [11, 12] and (iii) cell-soluble
factor interactions [13]. One of the most interesting and relatively
under-studied areas of study involving interactions between cells and
their environment concerns extracellular membrane vesicles known
as microparticles/microvesicles (MPs). MPs are released into the
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extracellular environment by a variety of cell types [14–21] and are
divided into two groups, exosomes and ectosomes, based on size
(50–1000 nm in diameter for ectosomes [14, 22], 50–100 nm for
exosomes [23]), composition and origin. Exosomes are enriched in
tetraspanins, milk fat globule-EGF factor 8 (MFG-E8) and MHC class
II molecules [23], while ectosomes are associated with their own set
of markers, including MMPs [24, 25]. Ectosomes are formed directly
by ectocytosis [22, 24, 26], while exosomes originate from multive-
sicular bodies (MVBs) that result when endosomes bud inwards into
their lumens [27–29]. Exosomes are released as MVBs fuse with the
plasma membrane and release their intraluminal vesicles. Both exo-
somes and ectosomes are distinct from apoptotic bodies, which are
larger (1–4 lm), formed at the end of apoptosis, and are usually
immediately taken up by macrophages [30, 31].
Interestingly, MPs contain membrane and cytosolic components
that can be transferred from one cell to another as the particles are
released and fuse with neighbouring cells. For example, exosomes
released by human mast cell lines are capable of transferring mRNAs
and microRNAs to other mast cells. Once inside the recipient cell, this
‘exosomal shuttle RNA’ is functional and affects cell behaviour [32].
MPs also contain a wide range of membrane and cytosolic proteins
[33, 34] that can also be shuttled between cells. MPs have been
shown to mediate the intercellular transfer of epidermal growth factor
receptor [35, 36], tissue transglutaminase [37] and chemokine recep-
tor 5 [38]. In all these cases, the recipient cell exhibited altered behav-
iour in response to the transfer of biomolecules via MPs.
Microparticles also signal to recipient cells independent of biomo-
lecular transfer by acting as circulating signalling complexes. Indeed,
MPs have been shown to present bioactive signalling molecules of
their surfaces, including Wnt [39] and Hedgehog ligands [40, 41].
MPs also contain internalized growth factors, such as VEGF [42],
fibroblast growth factor-2 (FGF-2) [43] and interleukin-1b (IL-1b)
[44], which are released upon degradation. These membrane-associ-
ated growth factors bind receptors on the receiving cells and activate
various cell behaviours, including migration [39], cytokine release
[45, 46], prostaglandin production [47], MMP expression [46] and
signalling pathway activation [45].
As stem cells multipotent for mesenchymal lineages, MSCs are
profoundly influenced by signals originating from their local environ-
ments, signals that derive, in part, from neighbouring cells. ECs and
CCs, both of which are included in the long list of cell types that release
MPs [19, 20, 25] and, by virtue of their physical proximity, probably
interact closely with MSCs. This study considers whether interactions
among ECs, CCs and MSCs include MP-mediated signalling and how
MP signalling influences the functional activities of MSCs.
Materials and methods
Cell culture
Human MSCs were isolated from hip replacement surgical waste col-
lected from three separate patients according to previously published
protocols [48] with Institutional Review Board approval. Briefly, femur
head bone marrow was repeatedly flushed with DMEM by using a
25-gauge syringe. The medium was collected and passed through a
70 lm mesh filter. The cells were pelleted by centrifugation at 200 9 g
for 5 min and then resuspended in growth media [DMEM supplemented
with 10% lot-selected foetal bovine serum (FBS) + 1% penicillin and
streptomycin (PS)] and plated in tissue culture flasks. After 4 days,
fresh medium was added 1:1. After another 4 days, cells were trypsi-
nized and passaged. The resultant cells were referred to as passage 1.
MSCs were used in experiments at passage 3, which were repeated as
3 experimental replicates with two patients each. Isolated MSC popula-
tions were validated with flow cytometry analysis of cell surface marker
expression. MSCs were trypsinized, and cell suspensions were washed
in PBS/1% FBS, blocked in 10% mouse serum, probed with PE-conju-
gated isotype controls IgG1,j and IgG2a,j) or PE-conjugated primary
antibodies (anti-CD73, CD90, CD105, CD45, CD19, CD34 and CD14),
fixed with 4% paraformaldehyde and analysed with a BD FACSAria II for
PE (488k laser, 575/25BP filter, Blue-2 detector) fluorescence. All iso-
type controls and PE-conjugated antibodies were purchased from BD
Biosciences (San Jose, CA, USA). MSCs were positive for CD73, CD90
and CD105 and negative for hematopoietic markers CD45, CD19, CD34
and CD14 (Fig. S1).
The human dermal microvascular EC line HMEC-1 was maintained in
the EC medium EGM-2-MV (Lonza, Walkersville, MD, USA), consisting of
a basal media supplemented with FBS (5%), human epidermal growth
factor (hEGF) (10 ng/ml), hydrocortisone (1 lg/ml), gentamicin (50 lg/
ml)/amphotericin-B (50 ng/ml; GA), human recombinant fibroblast
growth factor-beta (hFGF-b), VEGF, insulin-like growth factor (R3-IGF-1)
and ascorbic acid (the concentrations of hFGF-b, VEGF, R3-IGF-1 and
ascorbic acid included as part of the EGM-2-MV medium kit are not dis-
closed by the manufacturer). The human fibrosarcoma CC line HT1080
was maintained in a-MEM supplemented with 10% FBS and 1% PS.
MP isolation
EC and CC cultures to be used to generate MPs were washed with
PBS and cultured in serum-free (SF) Phenol Red-free (PF) EC medium
containing hEGF, hydrocortisone, hFGF-b, VEGF, R3-IGF-1, ascorbic
acid, and GS and supplemented with Insulin-Transferrin-Selenium for
24 hrs. [Note: We have found that the addition of these supplements
is essential for maintaining EC viability over 24 hrs of serum starvation
and, subsequently, avoiding contamination of harvested MPs with
apoptotic bodies (Fig. S2)]. Cell-conditioned medium (CM) was cleared
of cells and debris through sequential centrifugation at 600 9 g for
15 min and then at 1500 9 g for 15 min and ultracentrifuged for
2 hrs at 100,000 9 g at 4°C using a Beckman XL-70 Ultracentrifuge
(SW40Ti rotor). The ultracentrifugation pellets, referred to here as
MPs, were resuspended in either SF PF medium M199 (Invitrogen) or
protein collection buffer (Millipore) for analysing by Western blot. The
non-pelleted supernatants, referred to here as Sup, were collected and
concentrated via 3 kD MWCO spin concentrators (Millipore). MP and
Sup aliquots were analysed by BCA for protein concentration.
The protocol described above was used to isolate MPs for experi-
ments except for two exceptions. The first involved EC MP characteriza-
tion experiments, where a differential centrifugation protocol was
employed to yield ectosome and exosome vesicle fractions of total MP
populations [19, 49]. EC-conditioned media was spun at 300 9 g for
15 min followed by 2000 9 g for 15 min to clear cells and debris, and
then spun at 10,000 9 g for 30 min at 4°C to pellet ectosomes, which
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were resuspended in either medium M199 or protein collection buffer.
The supernatant was centrifuged at 100,000 9 g for 1 hr at 4°C to pel-
let exosomes, which were again collected in either M199 medium or
protein collection buffer.
The second exception involved experiments validating GFP localiza-
tion to both MP and Sup fractions in samples collected from ECs trans-
duced with lentiviral CMV-GFP constructs. ExoQuick-TCTM kits (System
Biosciences, Mountain View, CO, USA) were used to isolate microvesi-
cle and Sup samples according to the manufacturer’s instructions.
Electron microscopy
Ultracentrifugation pellets resuspended in PBS were applied to collo-
dion-coated grids, negatively stained with 1% phosphotungstic acid, pH
7.0 and observed with transmission electron microscopy (JEM-1011
Electron Microscope; JEOL USA, Peabody, MA, USA). Sizing of MPs
were carried out by measuring the dimensions of 250 randomly
selected MPs in the electron micrographs, and the data were analysed
with NIH ImageJ using the Particle Analysis function.
CMV-GFP lentiviral transduction
Endothelial cell cultures were washed with PBS and treated with a cus-
tom-made lentiviral CMV-GFP construct [50] (vector background similar
to Invitrogen CMV-GFP construct) diluted with EGM-2 MV media with-
out antibiotics, washed with PBS and fed full EGM-2 MV media. The
transduced EC cultures were cultured for an additional 48 hrs, washed
with PBS, and MP and Sup samples were collected as described above.
MSC cultures were then treated with MPs collected from either trans-
duced or untransduced ECs as described below.
Western blot
Microparticle and cellular protein samples were collected in Total Pro-
tein Collection (TPC) buffer (Millipore). MP pellets were resuspended in
TPC buffer (20 ll per ultracentrifuge tube) following ultracentrifugation.
To collect cellular proteins, cultures were washed with ice-cold PBS and
lysed with TPC buffer (10 ll/cm2). Protein samples were subjected to
reducing SDS-PAGE, transferred to polyvinylidene fluoride membranes,
probed with primary antibodies [anti-catalase, calnexin, HDAC1, Rab5,
caveolin, ERAB, GAPDH (EMD Millipore), LAMP-2, CD63 (Systems Bio-
sciences), HSP70 (Systems Biosciences), GFP, NF-jB p50 (EMD Milli-
pore), MMP-1, MMP-3, CCL-2, IL-6 and MMP-2], incubated with
horseradish peroxidase (HRP)-conjugated secondary antibodies, incu-
bated with chemiluminescent HRP substrate and imaged with a Foto-
dyne/Analyst FX CCD camera system. All primary antibodies were
purchased from Abcam unless otherwise specified. Densitometric analy-
ses of Western blots were performed with ImageJ.
Cell viability and proliferation
Endothelial cell viability and MSC proliferation were measured with the
CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS; Pro-
mega, Fitchburg, WI, USA) according to the manufacturer’s instructions.
In reporting MSC proliferation results, 490 nm absorbances were
related to cell numbers using standard curves.
Real-time RT-PCR
RNA was collected from cells treated with MPs by using the RNeasy Plus
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instruc-
tions. Cell cultures were trypsinized and washed extensively prior to RNA
isolation. The RT2 First Strand Kit (Qiagen) was used to convert mRNA into
cDNA according to the manufacturer’s instructions. Samples were analysed
via Signal Transduction PathwayFinder PCR Arrays (Qiagen).
MP–MSC interaction studies
Cell monolayer cultures were grown to 95% confluency in their respec-
tive growth media. Growth medium was then removed, and the cultures
were washed with PBS. MP or Sup was added at identical concentrations
(typically 25 lg/ml). MP vehicle control (MVC) in the form of SF PF med-
ium M199 or Sup vehicle control (SVC) in the form of SF PF EC medium
was added at identical volumes to MP and Sup samples, respectively.
Cells were cultured in treatments for 0, 4, 24, 48 or 72 hrs. The respec-
tive culture medium samples were collected from cells treated with MVC,
MP, SVC or Sup, centrifuged at 1050 9 g for 10 min to remove cell deb-
ris and stored at 80°C. Before collection, cell samples were washed 5
times in M199 and trypsinized for 5 min at 37°C. Defined trypsin inhibi-
tor (Invitrogen) was added and the cell suspensions were centrifuged at
200 9 g for 5 min. Cell pellets were washed with M199 medium and
harvested for protein or mRNA. Cell-free controls (CFCs) consisted of
identically treated tissue culture plastic. For isolation of cytoplasmic and
nuclear proteins, MP-treated cells were processed with the NE-PER
Nuclear Protein Extraction Kit (Thermo Fisher Scientific, Rockford, IL,
USA) according to the manufacturer’s instructions.
Migration studies
Migration studies were performed by using the Roche xCELLigence Sys-
tem (Roche Diagnostics, Indianapolis, IN, USA). The system consists of
plates of modified Boyden chambers, with upper and lower chambers
separated by a cell-permeable membrane lined with electrodes. Cells
are seeded into the top chambers, and candidate chemoattractants are
placed in the bottom chambers. As cells migrate across the membrane,
they contact electrodes, which the system reads as migrating cells.
MVC, MP, SVC and Sup were added to the bottom chambers. MP and
Sup samples were added at 100 lg/ml, and MVC and SCV samples
were added at identical volumes to MP and Sup samples, respectively.
Cells (40,000 per well) were added to top wells, and the plates were
scanned every 15 min for 24 hrs.
Live cell imaging
Endothelial cell cultures were incubated with CellMaskTM Orange (Invi-
trogen; 7 lg/ml) for 5 min at 37°C, washed extensively with PBS, and
fluorescently labelled MPs were collected as described above. Labelled
MP solution was diluted 1:100 in SF PF medium and administered to
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MSCs cultured on Mattek Dishes. MSC/MP cultures were analysed
with a custom-built live cell imaging system based on the Nikon
sweptfield confocal microscope. Images of the MSC/MP cultures were
taken every minute for 2 hrs, beginning at the time of MP-administra-
tion.
Flow cytometry quantification of biomolecular
transfer from EC MPs to MSCs
Confluent EC cultures were incubated with DiD (Invitrogen) diluted
1:200 in SF PF medium for 25 min at 37°C, washed extensively with
PBS, and DiD-labelled MPs were collected and used to treat MSCs
as described above. MP-treated MSCs were washed 5 times in M199
medium, collected by trypsinization, fixed with 4% paraformaldehyde,
incubated with 5 mM DAPI for 10 min, resuspended in PBS/1% FBS
and analysed with a BD FACSAria II for DAPI (405k laser, 450/50BP
filter, Vi-1 detector), GFP (488k laser, 530/30BP filter, Blue-1 detec-
tor) and DiD (640k laser, 670/30BP filter, Red-1 detector) fluores-
cence.
Statistics
Each sample was analysed over 3–5 experimental replicates. Quantified
results are expressed as the mean  SD, and significant differences
among experimental conditions were determined by two-tailed Student’s
t-tests for two-group comparisons or ANOVA for multiple group compari-
sons. Significance was considered at p < 0.05. Experiments involving
MSCs were repeated with cells isolated from at least 2 patients. Results
from the same representative patient are presented.
Results
The EC MPs used in this study exhibit
characteristics of ectosomes
Endothelial cell MPs were observed by negative staining and transmis-
sion electron microscopy as intact membranous structures (Fig. 1A).
The majority of isolated EC MPs (71%) were between 50 and 115 nm in
diameter (Fig. 1B), and, therefore, within the size ranges of both ecto-
somes and exosomes, but not apoptotic bodies [31, 51]. To aid in mak-
ing this distinction, EC MPs were analysed for the presence of various
organelle markers (Fig. 1C). Ectosomes, which originate from the
plasma membrane, are reported to include membrane, endoplasmic
reticulum (ER) and cytoplasmic components [49], while exosomes,
originating from intracellular MVBs, are reported to include endosomal
and lysosomal markers [34, 49, 52]. EC MPs were also analysed for
nuclear and mitochondrial markers, which are expressed by apoptotic
bodies [51]. The EC MPs isolated as part of this study were positive for
the ER marker calnexin, the plasma membrane marker caveolin and the
cytoplasmic marker GAPDH. The EC MPs were negative for the nuclear
maker HDAC1, the endosomal marker RAB5, the mitochondrial marker
ERAB and the lysosomal maker LAMP-2. These results suggest that the
EC MPs used in this study were ectosomes and not exosomes or apop-
totic bodies. Interestingly, the EC MPs were positive for the peroxisomal
marker catalase, which is in agreement with previous reports that
describe catalase expression by ectosomes [53]. All of the markers
tested were expressed by the parent ECs, while none of these markers
was detected in Sup samples.
A B
C D
Fig. 1 Endothelial cell (EC) microparticle
(MP) validation and characterization. (A)
Transmission electron micrograph of EC
MPs. (B) Size profile of EC MPs. (C) Wes-
tern blot analysis of organelle markers
among protein samples (10 lg total pro-
tein) collected from parent ECs (Cell) and
MP and Sup media fractions. (D) Western
blot analysis of ectosomal and ectosomal
markers among protein samples (5 lg
total protein) collected from unfractioned
MPs, and ectosome (Ecto) and exosome
(Exo) fractions isolated using differential
centrifugation. A commercially available
exosome positive control (Exo + Cntrl)
was also analysed.
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While the vast majority of the EC MPs used in this study exhibit
ectosome characteristics, our isolation procedure (i.e. single-step ul-
tracentrifugation), undoubtedly results in a heterogeneous vesicle
population that possibly includes exosomes. Thus, we used a differ-
ential centrifugation vesicle preparatory procedure to further charac-
terize EC MPs by fractionating the MP vesicle population into
ectosomes and exosomes. All three populations (unfractioned MP,
ectosomes, and exosomes) were analysed along with a commercially
available exosome positive control (Systems Biosciences) via Wes-
tern blot for various ectosomal and exosomal markers (Fig. 1D). The
same amount of total protein (5 lg) was analysed of each sample, so
vesicle population underrepresented in unfractionated MP prepara-
tions would be enriched in fractioned preparations of exosomes and
ectosomes. Unfractioned MP and ectosome vesicle populations were
positive for the ectosomal markers calnexin and caveolin, and nega-
tive for the exosomal markers Rab5, LAMP-2, CD63 and HSP70,
while the exosome fraction and positive control expressed exosomal,
but not ectosomal, markers. All samples tested were positive for the
peroxisomal marker catalase and the cytoplasmic marker GAPDH. We
also tested the effects of ectosome and exosome vesicle fractions on
MSCs, but did not detect significant differences in vesicle-induced cell
migration or proliferation (Fig. S3). Thus, these results suggest that
the vast majority of the vesicles used in this study can be classified
as ectosomes. As both ectosomes and exosomes performed compar-
atively in MSC-based assays, and given that exosomes make up a
very small fraction of EC MP vesicle population and that exosomes
are significantly more costly in terms of both time and supplies to
prepare, all further experiments described in this study were per-
formed by using unfractioned MP vesicle populations.
MPs transfer cellular components from ECs to
MSCs
To demonstrate MP interaction and fusion of EC MPs and MSCs,
live cell imaging was used to observe MSC cultures incubated with
fluorescently labelled EC MPs. MP and Sup were isolated from ECs
labelled with the membrane dye CellMaskTM Orange. Labelled MPs
were clearly observed as they descended onto and bound unla-
belled MSCs (Fig. 2). Upon binding, the MPs fused with the MSCs,
transferring their fluorescent membrane-associated dye to the MSC
surfaces over the 120 min assayed. These fluorescent membrane
patches localized with the point of contact between an MP and the
MSC surface. Serving as negative controls, MSCs incubated with
Sup samples collected from fluorescently labelled MSCs did not
exhibit fluorescent membrane patches over the time period
assayed. These results suggest that EC MPs bind and fuse with the
cell membranes of MSCs, and that EC components, in this case
membrane dye, are effectively transferred to MSCs via MPs, but
not non-MP secreted factors (Sup).
These experiments were next performed with EC MPs engineered
to contain cytosolic GFP. EC MP and ultracentrifugation supernatant
(Sup) samples were collected from EC cultures transduced with a len-
tiviral CMV-GFP construct. Samples collected from transduced cul-
tures contained significantly higher fluorescence measurements than
untransduced controls for all fractions (Fig. 3A). Thus, GFP was
transferred from the ECs to the MPs, but also to the Sup fraction.
(Note: To rule out the possibility that GFP inclusion in Sup samples
was because of incomplete MP versus Sup fractionation, and vice
versa, MP and Sup samples collected from transduced ECs were also
isolated by an alternative approach by using ExoQuick-TCTM kits. GFP
was detected by Western blot in all samples regardless of isolation
protocol (Fig. S4), confirming that GFP is included in both MP and
Sup media fractions). MSCs were treated with MP and Sup GFP
(25 lg protein/ml). After 1, 2 or 3 days, MSC cell lysates were col-
lected and analysed (20 lg protein per sample) via fluorescence
spectroscopy (Ex 488/Em 525) (Fig. 3B). Only lysates collected from
MSCs treated with GFP-MP exhibited significantly enhanced fluores-
cence compared with vehicle controls (fractions collected from un-
transduced ECs). MP-transferred GFP was retained for at least
3 days. These results were confirmed with Western blot (Fig. 3C), as
GFP was detected only in MSCs treated with GFP-MPs, indicating that
Fig. 2 Live cell imaging of mesenchymal stem cells (MSCs) interacting with fluorescently labelled endothelial cell (EC) microparticles (MPs). An
MSC was tracked during its interactions with CellMaskTM Orange I-labelled EC MPs over 120 min. As a negative control, an MSC that had been incu-
bated for 120 min with Sup collected from fluorescently labelled ECs is presented. Images displayed in the top row are combinations of bright field
and fluorescence (Ex 488/Em 575), while images in the bottom row are fluorescence only. Cell outlines are depicted in bottom row images by a
solid white line; bar = 1 lm.
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only MP-associated GFP was transferred to MSCs. Again, this trans-
ference was retained for at least 3 days. (Note: Neither GFP mRNA
nor lentiviral RNA/protein was ever detected in MSCs incubated with
MPs isolated from transduced cells (data not shown), suggesting that
the GFP detected in MSCs results from protein transfer from MPs to
MSCs.) Thus, only MP-associated proteins were taken up and
retained by MSCs, suggesting a level of cellular specificity in which
MP biomolecules, but not secreted factors, are shuttled between
MSCs and ECs.
The above experiments were combined to yield a new quantita-
tive method to evaluate MP-cell interactions and biomolecular
transfer. EC cultures were transduced with lentiviral CMV-GFP and
labelled with the fluorescent membrane dye DiD, yielding EC MPs
co-labelled with DiD and GFP. MSCs were incubated with DiD+
GFP+ MPs (100 lg protein/ml) for 24 hrs, stained with DAPI and
analysed via flow cytometry (Fig. 3D). Selecting for DAPI+ popula-
tions ensured that MSCs, not MPs, were included in analysis. Hav-
ing shown that lipophilic fluorescent dyes are quickly and efficiently
transferred from labelled MPs to MSCs during MP-MSC interac-
tions, DiD+ populations were selected to concentrate analysis on
MSCs that have interacted with MPs. DAPI+ DID+ populations were
analysed for GFP fluorescence by using MSCs treated with DiD+
GFP MPs to set gating strategies for GFP fluorescence. Of the
MSCs treated with DiD+ GFP+ MPs, clear populations of DiD+ GFP+
MSCs were detected, representing cells that had taken up and
retained both DiD and GFP from MPs. Thus, MSCs populations that
received both membrane and cytosolic proteins from MPs were
identified.
A
B
C
D
Fig. 3Microparticles (MPs) transfer bio-
molecules from endothelial cells (ECs) to
mesenchymal stem cells (MSCs). (A) Flu-
orescence spectroscopy analysis of whole
cell (EC), MP, and Sup protein samples
(20 lg) collected from ECs transduced
with (GFP) or without (Control) CMV-GFP
lentivirus. (B) Fluorescence spectroscopy
analysis of cell lysates (20 lg) collected
from MSCs incubated with MP or Sup
(25 lg protein/ml) collected from untrans-
duced (control) or GFP-transduced (GFP)
ECs for 1, 2 or 3 days. ***, p < 0.001.
(C) Western blot analysis of GFP contents
of lysates (20 lg) collected from MSCs
incubated with MP or Sup proteins col-
lected from GFP or control ECs for 1, 2,
or 3 days. (D) Flow cytometry analysis of
MSCs treated with DiD+ GFP- (gating con-
trol) or DiD+ GFP+EC MPs for 24 hrs. Q1
and Q2 denote DiD+ GFP-and DiD+GFP+
MSC populations, respectively. Quantifica-
tion of these MSCs from 3 independent
experiments is presented in the histogram
on the right. #, p < 0.001.
ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
2377
J. Cell. Mol. Med. Vol 18, No 12, 2014
MPs induce MSC migration and proliferation
Mesenchymal stem-cell migration in response to MPs was mea-
sured by using the Roche xCELLigence System consisting of Tran-
swells with electrodes coating one side of the cell-permeable
membrane. Chemoattractant placed in the bottom chamber induces
migration in cells placed in the top, and the system measures cells
as they crawl through the membrane and contact the electrodes.
This allows for very sensitive detection of migrating cells in real
time. The system was used to measure the MSC migration dose
response to EC MPs (0–100 lg protein/ml) (Fig. 4A). The range
tested induced a direct response in MSC migration, indicating that
MSC migration towards EC MPs is concentration-dependent. Fig-
ure 4B shows representative plots of migration in response to EC
MVC, MP, SVC or Sup (100 lg protein/ml) over 24 hrs. Both EC
MPs and Sup significantly induced chemotaxis in MSCs compared
with vehicle controls. EC MPs were significantly more chemoattrac-
tive to MSCs than EC Sup.
Mesenchymal stem cells naturally home to tumours, where they
interact with CCs [9, 10]. Furthermore, we sought to include a cell-
type control to determine whether the effects observed with EC
MPs were specific for epithelial-derived vesicles or common for
MPs regardless of parent cell identity. Thus, MPs derived from the
mesenchymal CC line HT1080 were included in this study, and
MSC migration induced by either EC- or CC-derived MPs were
compared (Fig. 4C). (Note: CC MPs exhibited similar expression of
organelle markers when compared with EC MPs (Fig. S5), suggest-
ing that both sets of MPs are produced via similar mechanisms
and predominantly consist of ectosomes.) CC MPs were signifi-
cantly more chemoattractive to MSCs than EC MPs, and only CC
Sup was significantly chemoattractive to MSCs compared with vehi-
cle controls. Thus, the identity of the parent cell type clearly affects
the degree to which MPs induce MSCs to migrate. These experi-
ments were expanded to test the effects of EC- and CC-derived
MPs on CCs and ECs to determine if MP effects on migration dif-
fered with the receiving cells. As in MSCs, CC MPs induced more
migration in ECs and CCs than EC MPs (Fig. 4D and E). Interest-
ingly, EC-derived Sup, but not CC Sup, induced migration in CCs
and ECs.
Finally, the effects of CC and EC MPs on MSC proliferation were
considered. Identical numbers of MSCs were plated and treated with
EC- or CC-derived MPs or Sup under SF conditions for 0 or 72 hrs
and analysed for proliferation by using MTS assays (Fig. 4F). Both
EC-and CC-derived MPs and Sup significantly enhanced MSC prolifer-
ation compared with vehicle controls.
MPs activate MSC cytokine secretion
To investigate the effects of MPs on MSC cytokine secretion, MSCs
were treated with EC- or CC-derived MPs or Sup (25 lg protein/ml)
for 72 hrs and CM was collected and analysed by MMP-1, MMP-3,
CCL-2/MCP-1 and IL-6 Western blots (Fig. 5A). Blots of MMP-2, an
MSC-secreted factor that does not respond to MPs or Sup, were
included as loading controls in Western blots and used for normaliza-
tion in densitometric analyses (Fig. 5B). CFCs consisting of identically
treated cell-free tissue culture plastic (TCP) were also included. CC
MPs increased MSC secretion of MMP-1, MMP-3, CCL-2/MCP-1 and
IL-6 compared with vehicle control. EC MPs also increased MSC
secretion of MMP-1, MMP-3, CCL-2/MCP-1 and IL-6 (Fig. S6), but
only CCL-2/MCP-1 was induced at levels comparable to those stimu-
lated by CC MPs. CC and EC Sup both increased MSC secretion of
MMP-1, MMP-3, CCL-2/MCP-1 and IL-6. CC Sup was significantly
more potent in its increases compared with EC Sup, particularly in the
case of IL-6. None of the molecules analysed was present in any of
the CFC controls, indicating that whatever changes seen in MSC sam-
ples were because of cell-secreted molecules and not because of mol-
ecules merely being added as part of the treatments (MMP-1 and
CCL-2 were detected in EC CM collected after 3 days. However, the
EC-derived products used as treatments in this experiment were col-
lected after 24 hrs, and levels of these proteins were undetectable in
CFC control samples.)
These experiments were repeated with ECs and CCs treated with
CC- and EC-derived MPs and Sup, respectively, to determine whether
MP effects on cytokine secretion differed with the receiving cells
(Fig. 5A). CC Sup increased EC secretion of MMP-1, MMP-3, CCL-2/
MCP-1 and IL-6 compared with vehicle controls. EC Sup increased
CC secretion of MMP-1. ECs were unresponsive to EC Sup, and CCs
were unresponsive to CC sup (data not shown). Thus, both ECs and
CCs were responsive to non-MP factors secreted by each other, but
not to their own. Interestingly, neither ECs nor CCs responded to MPs
derived from either cell type. Thus, MSCs appear to be particularly
responsive to MPs.
MPs activate NF-jB signalling in MSCs
The following experiments were aimed at identifying the MSC sig-
nalling pathways activated by EC and CC MPs under control condi-
tions. To identify likely candidate signalling pathways activated by
MPs in MSCs, cultures of MSCs treated with EC or CC MPs for
4 hrs were analysed with Signal Transduction PathwayFinder PCR
Arrays (Fig. 6A). These arrays probe for expression of known tran-
scription targets of various signalling pathways, including the Wnt,
hedgehog, TGF-b, PI3 kinase/AKT, Jak/SRC, p53, NFAT, CREB, Jak-
Stat, PKC, phospholipase C, LDL and NF-jB pathways. Treatment
with MPs and/or Sup induced increased MSC expression of several
transcription targets compared with vehicle controls, including
BIRC3, BMP2, CCL2, CCL20, CSF2, ICAM1, IL1A, IL8, IRF1, MYC,
NFKB1, PECAM, PTGS2 and TNF. The majority of these genes,
BIRC3, CCL20, ICAM1, IL1A, IL8, NFKB1, PECAM and TNF, are
transcriptional targets of the NF-jB pathway, identifying NF-jB as a
likely candidate signalling cascade activated by Sup and MPs. To
validate MSC NF-jB activation, MSCs treated with EC or CC MPs
or Sup for 1 hr were separated into cytoplasmic and nuclear pro-
tein fractions and analysed by NF-jB p50 Western blots (Fig. 6B).
Cytoplasmic/nuclear protein fractionation was validated with HDAC1
and GAPDH Western blots, which showed HDAC1 and GAPDH
localization to nuclear and cytoplasmic fractions, respectively. Den-
sitometric analysis of Western blot data confirmed significant
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increases in the ratio of nuclear to cytoplasmic NF-jB p50 in
response to MP and Sup stimulation compared with vehicle con-
trols (Fig. 6C). Thus, treatment with EC and CC MP and Sup
caused significant increases in nuclear NF-jB p50 compared with
vehicle controls, which agreed with PCR array results and sug-
gested activation of the NF-jB signalling pathway in MSCs by
EC- and CC-secreted factors, including MPs.
Discussion
Intercellular interactions have traditionally been thought to include
cell–cell, cell–matrix and cell-soluble factor interactions. However, a
fourth avenue of crosstalk involving MPs has proven to occupy a piv-
otal role in intercellular communication [54]. MPs are selectively
A B
C D
E F
Fig. 4Microparticles (MPs) induce mesen-
chymal stem cell (MSC) migration and
proliferation. (A) MSC chemotaxis in
response to endothelial cell (EC) MPs
(0–100 lg protein/ml) after 24 hrs. #,
p < 0.001, compared with vehicle control.
(B) Representative real-time migration
assay plot of MSC chemotaxis towards EC
MVC, MP, SVC, or Sup (100 lg protein/
ml) over 24 hrs. (C) MSC, (D) CC, (E) or
EC chemotaxis towards EC- or CC-derived
MPs and Sup (100 lg protein/ml) after
24 hrs. #, p < 0.001, compared with vehi-
cle control; ***, p < 0.001. (F) Effects of
treatment (72 hrs) with MP and Sup
(100 lg protein/ml) collected from ECs or
CCs on MSC proliferation. Fold changes of
0 represent no changes in cell numbers
compared with those at the start of the
experiments. #, p < 0.001, compared with
vehicle control.
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packaged with specific biomolecules, including protein, mRNA and
microRNA, as they are released by parent cells [54–56]. As stable
membrane enclosed vesicles, MPs are able to target to remote tis-
sues to effect traditional pathways of intercellular interaction. For
example, MPs contain membrane proteins, including cadherins and
other cell adhesion molecules, which, upon binding to receptors on
the receiving cell, activate signalling pathways and cellular responses
as if the parent and recipient cells were in direct physical contact
[57]. Matrix receptors on the surfaces of MPs also localize ECM mole-
cules to the membranes of receiving cells, effectively facilitating
cell–matrix interactions [37]. Finally, MPs release growth factors and
cytokines as they degrade, regulating their delivery to target cells
A
B
Fig. 5Microparticles (MPs) and Sup induce mesenchymal stem cell (MSC) cytokine secretion. (A) Western blot analysis of MSC-conditioned med-
ium (CM), endothelial cell-cell-conditioned medium (EC-CM), or CC-CM collected from cells treated with EC- or CC-derived MVC, MP, SVC, or Sup
(25 lg protein/ml) for 72 hrs. Cell-free controls (CFCs) were included to validate cell-secreted products. (B) Densitometric analysis of Western blots
pertaining to samples collected from MSCs. Bands from MMP-1, MMP-3, CCL-2, and IL-6 blots were quantified by using ImageJ and normalized to
corresponding MMP-2 bands. Results are from three experimental replicates. #, p < 0.05, compared with vehicle control; *, p < 0.05.
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[39–43]. However, MPs are also able to signal via intercellular trans-
ference of biomolecules, which occurs when the membrane of the
MP fuses with that of the receiving cell. Once incorporated by receiv-
ing cells, the transferred MP biomolecules may elicit biological
changes [32, 35–38, 58]. Thus, MPs are optimally suited for their
roles as a compact signalling platform, forming stimulatory com-
plexes with receiving cell surface receptors and transferring biomole-
cules to the membranes and interiors of recipient cells.
Here, we investigated the role of MPs and non-MP secreted fac-
tors (Sup) in signalling among MSCs, ECs and CC, cell types
known to interact under both physiological and pathological condi-
tions in vitro and in vivo [5, 9–12, 59, 60], observing key cell
responses in MSCs when treated with Sup and MPs. (Note: Inter-
estingly, in our hands, MSCs did not produce detectable levels of
MPs, despite several previously published reports to the contrary.
We believe that these discrepancies are because of MSC biological
state and source, as many of the studies that reported on MSC
MPs used commercially available MSCs [61, 62], whereas the
study presented here used low passage, freshly isolated primary
cells.) First, we showed that MPs transfer both membrane and
cytosolic molecules from ECs to MSCs in a process that requires
packaging of biomolecules within MPs. Only MP-associated mole-
cules are taken up and retained by MSCs, suggesting that EC MPs
are necessary and sufficient for transferring membrane and cyto-
solic components between ECs and MSCs.
Microparticle-mediated signalling between MSCs and ECs inde-
pendent of biomolecular transference was also observed. First, MPs
were shown to be particularly chemoattractive to MSCs, and MPs iso-
lated from a fibrosarcoma cell line were significantly more chemoat-
tractive to MSCs than EC MPs. Given that increased levels of MPs are
released at sites of injury/cancer and in response to cytokine stress
[25, 63–66], and that MSCs home to sites of injury and cancer [9, 10,
67–69], these results suggest a role for MPs in attracting MSCs and
other cells to sites of injury/cancer. These results also suggest that
A
B
C
Fig. 6Microparticles (MPs) and Sup acti-
vate mesenchymal stem cell (MSC) NF-jB
signalling. (A) MSCs treated with endothe-
lial cell (EC) or CC MPs or Sup (100 lg
protein/ml) were analysed with Signal
Transduction PathwayFinder PCR Arrays,
which measures changes in known tran-
scription targets of cellular signalling cas-
cades. Fold changes of 0 represent
vehicle control values. Dashed lines mark
fold changes of 2 and 4. (B) MSCs were
treated with EC or CC MVC, MP, SVC or
Sup for 1 hr, separated into cytoplasmic
(C) and nuclear (N) fractions, and analy-
sed by NF-jB p50, HDAC1 and GAPDH
Western blots. (C) Densitometric analysis
of Western blots data. NF-jB p50 bands
were quantified, and nuclear values were
normalized to corresponding cytoplasmic
values. Results are from three experimen-
tal replicates. #, p < 0.05, compared with
vehicle control.
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the identity of the parent cells of MPs affect the migration response
of the receiving cells.
Analysis of the effects of MPs on MSC cytokine secretion revealed
that both Sup and MPs activate secretion of MMP-1, MMP-3, CCL-2
and IL-6. Cytokines such as these are responsible for many of the tro-
phic effects reported for MSCs. For example, MSC-secreted IL-6 has
been shown to maintain MSC stemness [70], promote adenocarci-
noma tumour growth [71], delay neutrophil apoptosis and inhibit pro-
genitor cell differentiation into dendritic cells by impairing their
antigen-presenting function [72–78]. CCL-2/MCP-1 regulates MSC
homing to breast cancer tumours [10]. MSC-secreted MMP-3 has
been linked to the pro-angiogenic effects of MSCs [79]. MMP-1 is
secreted by MSCs as they migrate towards tumours [80], and having
reported here that MPs induce both chemotaxis and MMP-1 expres-
sion in MSC, it appears that MPs are particularly supportive of MSC
migration. As in the migration studies, MP effects on MSC cytokine
secretion differed with the identity of the parent cells, as CC MPs
proved to be significantly more inductive than EC MPs. On the other
hand, both EC and CC MPs activate MSC NF-jB signalling at compa-
rable levels, suggesting that the particular potency of CC MPs may be
grounded in properties unrelated to this particular intracellular signal-
ling cascade. Furthermore, MP effects on cytokine secretion were
heavily dependent on the identity of the receiving cell. In fact, of the
three cell types tested, MSCs were the only cell type that responded
to MP treatment in terms of the tested cytokines. Thus, MSCs may be
particularly responsive to MP signalling, and we are currently con-
ducting studies aimed at determining the mechanisms underlying the
abilities of EC and CC MPs to specifically target MSCs.
In summary, we have demonstrated signalling between MSCs and
MPs in vitro. Our findings that MPs activate MSC migration and cyto-
kine secretion have potential applications towards elucidating the
mechanisms underlying MSC homing to and modulation of injury and
cancer sites. Our studies have also revealed that the identity of the
parent and target cells affects how MP signals are received and inter-
preted, indicating an exciting and complex role of MPs in transferring
disease state information between cells. Thus, this study has revealed
unexpected layers of sophistication regulating MP-mediated signal-
ling between ECs and MSCs and provides evidence towards establish-
ing MPs among the functional communication channels of EC-MSC
crosstalk.
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